載入...
Targeted therapy for idiopathic pulmonary fibrosis: where to now?
Idiopathic pulmonary fibrosis (IPF) is an aging-associated recalcitrant lung disease with historically limited therapeutic options. The recent approval of two drugs, pirfenidone and nintedanib, by the United States Food and Drug Administration (FDA) in 2014 has heralded a new era in its management....
Na minha lista:
| 發表在: | Drugs |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939080/ https://ncbi.nlm.nih.gov/pubmed/26729185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-015-0523-6 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|